Familial hypercholesterolaemia
Inherited severe LDL elevation · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Familial hypercholesterolaemia is an inherited disorder of LDL-receptor handling causing lifelong very high LDL-C and premature atherosclerosis. Early diagnosis using clinical criteria and aggressive LDL lowering dramatically reduce cardiovascular risk.
Red flags
- LDL-C >13 mmol/L suggesting homozygous FH
- Premature coronary disease in the patient or a young relative
- Aortic stenosis murmur (supravalvular/valvular involvement in HoFH)
- Tendon xanthomata or corneal arcus before age 45
- Recurrent cardiovascular events despite treatment
Assessment
Differential diagnosis
- Polygenic hypercholesterolaemia
- Secondary hyperlipidaemia (hypothyroidism, nephrotic, cholestasis)
- Familial combined hyperlipidaemia
- Sitosterolaemia
- Lipoprotein(a) elevation
- Drug-induced dyslipidaemia
Investigations
- Fasting lipid profile (LDL-C often >5 mmol/L untreated)
- Exclude secondary causes: TSH, glucose, renal/liver function, urine protein
- Lipoprotein(a) level once in a lifetime
- Clinical scoring (Dutch Lipid Clinic or Simon Broome criteria)
- Genetic testing for LDLR, APOB, PCSK9 variants
- Cascade screening of first-degree relatives
Management
- Suspect FH with very high LDL-C, tendon xanthomata or premature CAD family history
- Apply a validated diagnostic score and exclude secondary causes
- Arrange genetic testing and cascade screening of relatives
- Set an LDL-C target of <2.6 mmol/L (primary prevention) or <1.4 mmol/L (established CVD)
- Start high-intensity statin at maximum tolerated dose
- Add ezetimibe early if target not reached
- Add a PCSK9 inhibitor or inclisiran when still above target
- Consider bempedoic acid in statin intolerance
- Reinforce lifestyle: diet, exercise, smoking cessation
- Assess and treat other risk factors aggressively
- Consider lipoprotein apheresis in homozygous or refractory severe cases
- Plan lifelong follow-up and family screening
Drugs & doses
Rosuvastatin 20-40 mg PO OD (or atorvastatin 40-80 mg OD)
Ezetimibe 10 mg PO OD
Alirocumab 75-150 mg SC every 2 weeks (or evolocumab 140 mg SC every 2 weeks)
Inclisiran 284 mg SC at 0 and 3 months then 6-monthly
Bempedoic acid 180 mg PO OD if statin intolerant
Evinacumab (ANGPTL3 inhibitor) IV for homozygous FH in specialist settings
Disposition
Refer to a lipid clinic; coordinate family cascade screening. Specialist apheresis/genetics for homozygous or refractory disease.
Complications & pitfalls
- Premature coronary artery disease
- Aortic valve and root atherosclerosis
- Peripheral and carotid atherosclerosis
- Statin intolerance limiting therapy
- Under-treatment of relatives without screening
Exam pearls
- Diagnosis should trigger cascade screening of all first-degree relatives
- LDL-C does not need to be fasting for diagnosis in most cases
- Homozygous FH presents in childhood and needs specialist lipid-clinic care
- PCSK9 inhibitors and inclisiran offer major additional LDL lowering
- Lp(a) should be measured once as it modifies risk independently
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.